Sarsour, Khaled <br/><br/>
The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.  [electronic resource] 

 -  Clinical and experimental rheumatology   
 - 189-94 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0392-856X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--diagnosis<br/>Case-Control Studies<br/>Female<br/>Genotype<br/>Humans<br/>Linear Models<br/>Male<br/>Middle Aged<br/>Pharmacogenetics<br/>Phenotype<br/>Polymorphism, Genetic<br/>Receptors, IgG--genetics<br/>Rituximab<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors